• Explore /
  • Poster
  • / A phase I study of neoadjuvant cisplatin (C), docetaxel (D) and nintedanib (N) for resectable non-small cell lung cancer (NSCLC).

A phase I study of neoadjuvant cisplatin (C), docetaxel (D) and nintedanib (N) for resectable non-small cell lung cancer (NSCLC).

Abstract Poster

Authors

null

Tina Cascone

The University of Texas MD Anderson Cancer Center, Houston, TX

Tina Cascone , Boris Sepesi , Heather Y. Lin , Neda Kalhor , Jianjun Zhang , Frank V. Fossella , Anne S. Tsao , Vincent K. Lam , Charles Lu , Frank Mott , George R. Simon , Mara Antonoff , Reza J. Mehran , David C. Rice , Ara A. Vaporciyan , Myrna Godoy , J. Jack Lee , Stephen Swisher , William Nassib William Jr., John Heymach

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Local-Regional Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02225405

Citation

J Clin Oncol 36, 2018 (suppl; abstr 8555)

DOI

10.1200/JCO.2018.36.15_suppl.8555

Abstract #

8555

Poster Bd #

161

Abstract Disclosures

Similar Posters

First Author: Mikako Tamba

First Author: Toshiharu Hirose

First Author: Christian Grohé

First Author: Julie R. Brahmer